• 1
    Rosencher N, Boucebci KJ, Menichella G, et al. Orthopaedic surgery transfusion haemoglobin European overview: the OSTHEO study (extended abstract). Transfus Clin Biol 2001; 8:2113.
  • 2
    Marquet RL, Hoynck van Papendrecht MA, Busch OR, Jeekel J. Blood donation leads to a decrease in natural killer cell activity: a study in normal blood donors and cancer patients. Transfusion 1993; 33:36873.
  • 3
    Landers D. F., Hill GE, Wong KC, Fox IJ. Blood transfusion-induced immunomodulation. Anesth Analg 1996; 82:187204.
  • 4
    Innerhofer P, Luz G, Spotl L, et al. Immunologic changes after transfusion of autologous or allogeneic buffy coat-poor versus white cell-reduced blood to patients undergoing arthroplasty. I. Proliferative T-cell responses and the balance of helper and suppressor T cells. Transfusion 1999; 39:108996.
  • 5
    Adamson J. Perisurgical use of epoetin alfa in orthopedic surgery patients. Semin Hematol 1996; 33(2 Suppl 2):558.
  • 6
    de Andrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop 1996; 25:53342.
  • 7
    Goldberg MA, McCutchen J. W., Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996; 25:54452.
  • 8
    Feagan BG, Wong CJ, Kirkley A, et al. Erytropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. Ann Intern Med 2000; 133:84554.
  • 9
    Olijhoek G, Megens JG, Musto P, et al. Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion 2001; 41:95763.
  • 10
    Blumberg N. Allogeneic transfusion and infection: Economic and clinical implications. Semin Hematol 1997; 34(3 Suppl 2):3440.
  • 11
    Houbiers JG, van de Velde CJ, van de Watering LM, et al. Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: a prospective study. Transfusion 1997; 37:12634.
  • 12
    Vamvakas EC, Carven JH. Allogeneic blood transfusion, hospital charges, and length of hospitalization. A study of 487 consecutive patients undergoing colorectal cancer resection. Arch Pathol Lab Med 1998; 122:14551.
  • 13
    Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81:210.
  • 14
    Carson JL, Altman DG, Duff A, et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion 1999; 39:694700.
  • 15
    Innerhofer P, Walleczek C, Luz G, et al. Transfusion of buffy coat-depleted blood components and risk of postoperative infection in orthopedic patients. Transfusion 1999; 39:62532.
  • 16
    Sonnenberg FA, Gregory P, Yomtovian R, et al. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion 1999; 39:80817.
  • 17
    Weber EWG et al. Perioperative blood transfusions and delayed wound healing after hip replacement surgery: effects on duration of hospitalisation. Thesis, University Maastricht, The Netherlands.